Intellectual Property
May 22, 2024
IP strategies for AI-minded life sciences companies
See more on IP strategies for AI-minded life sciences companiesBy Irene Yang and Brooke Böll, Sidley Austin LLP
Life sciences companies are increasingly using AI in wide-ranging ways, including protein design, clinical trial analysis, and disease diagnosis. Although AI-related patent filings in the USPTO have accelerated, it is increasingly difficult to get an application granted. See 2024 AI Index Report, Chapter 1.2 ($95
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In